Which Is a Better Investment, ACADIA Pharmaceuticals Inc or Alkermes Plc Stock?

view original post

Sifting through countless of stocks in the Biotechnology & Medical Research industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in ACADIA Pharmaceuticals Inc or Alkermes Plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how ACADIA Pharmaceuticals Inc and Alkermes Plc compare based on key financial metrics to determine which better meets your investment needs.

About ACADIA Pharmaceuticals Inc and Alkermes Plc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The Company has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The Company also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

Alkermes Public Limited Company is an integrated biopharmaceutical company. It is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

Latest Biotechnology & Medical Research and ACADIA Pharmaceuticals Inc, Alkermes Plc Stock News

As of January 18, 2023, ACADIA Pharmaceuticals Inc had a $2.9 billion market capitalization, compared to the Biotechnology & Medical Research median of $103.5 million. ACADIA Pharmaceuticals Inc’s stock is NA in 2023, NA in the previous five trading days and down 22.04% in the past year.

Currently, ACADIA Pharmaceuticals Inc does not have a price-earnings ratio. ACADIA Pharmaceuticals Inc’s trailing 12-month revenue is $511.5 million with a -42.5% net profit margin. Year-over-year quarterly sales growth most recently was -0.7%. Analysts expect adjusted earnings to reach $-1.317 per share for the current fiscal year. ACADIA Pharmaceuticals Inc does not currently pay a dividend.

Currently, Alkermes Plc does not have a price-earnings ratio. Alkermes Plc’s trailing 12-month revenue is $1.1 billion with a -11.4% net profit margin. Year-over-year quarterly sales growth most recently was -14.2%. Analysts expect adjusted earnings to reach $0.255 per share for the current fiscal year. Alkermes Plc does not currently pay a dividend.

How We Compare ACADIA Pharmaceuticals Inc and Alkermes Plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at ACADIA Pharmaceuticals Inc and Alkermes Plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions